Journal of Clinical Oncology
Articles in this Issue
Rare immune-related adverse events: A retrospective analysis from a single-center cohort study.
e14615 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the management of multiple malignancies. Off-target toxicity can lead to immune...
Sex-based differences in complications in patients with diffuse large B cell lymphoma receiving axicabtagene ciloleucel therapy.
e19057 Background: Improvement in quality of care and the introduction of novel therapies have led to a better prognosis of diffuse large B cell lymphoma...
The utilization of patient-derived organoids as a platform for predicting the efficacy of anti-cancer drugs: Chemotherapy, targeted therapy, and immunotherapy.
e15102 Background: Cancer is one of the leading causes of mortality worldwide. Current treatments are confronted with limitations, including drug resistan...
Cost-effective cancer care: The role of oncology biosimilars in generating cost savings.
11033 Background: Biosimilar versions of biologic drugs (reference drugs) present a promising opportunity to reduce healthcare costs. Although not labeled...
Transforming liver tumor segmentation: A comprehensive meta-analysis of deep learning approaches.
e13653 Background: Precise segmentation of hepatic neoplasms is essential for effective diagnosis and treatment planning. Manual segmentation of abdominal...
Factors associated with frailty in vulnerable hematopoietic cell transplantation candidates.
6552 Background: Allogenic hematopoietic cell transplantation (allo-HCT) is increasingly offered to older patients and those with comorbidities. Frailty,...
Improving outcomes in gyneco-oncology in late and last line setting: Real-world data from the molecular tumor board registry trial at the Comprehensive Cancer Center Freiburg (Germany).
e17655 Background: Molecular tumor boards (MTBs) play a crucial role in personalized medicine in Germany, guiding the treatment of patients who have exhau...
Cervical cancer mortality trends and disparities in women of the United States: A two-decade retrospective analysis.
e17509 Background: Cervical cancer is a cancerous growth of cells in the cervix. It usually has an insidious development. Most cervical cancers are squamo...
Disparities in demographics, clinical features, and outcomes of early-onset colon cancer in the US.
e15700 Background: The incidence of early-onset colon cancer (EO-CC) is rising, but it remains unclear whether EO-CC represents a biologically distinct en...
An electronic patient-reported outcomes (ePRO)-directed virtual model for addressing oncology supportive care needs.
e13886 Background: Virtual oncology care models using electronic patient-reported outcomes (ePRO)-based interventions improve outcomes, but limited access...
SOGUG-NEOWIN: A phase 2, open-label, multicenter, multinational interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and the combination of ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) harboring FGFR gene alterations.
TPS4628 Background: The standard treatment for nonmetastatic MIBC is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy (RC). However...
Real-world safety among patients with locally advanced or metastatic urothelial cancer (la/mUC) treated with first-line (1L) systemic regimens: Results from the ELEVATE UC-I study.
e16554 Background: Recent advances in the treatment (tx) of la/mUC include immune checkpoint inhibitors (ICIs) and antibody drug conjugates (ADCs) alone o...
Long-term outcomes after discontinuation of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC) in the POD1UM-201 trial.
9538 Background: Retifanlimab is a humanized programmed cell death protein-1 (PD-1)–blocking antibody that is approved for treatment of adults with metast...
Comparing real-world treatment patterns and outcomes of zanubrutinib and acalabrutinib in CLL/SLL at University of California academic health centers.
e23263 Background: Newer BTK inhibitors zanubrutinib (ZANU) and acalabrutinib (ACA) are preferred over first-generation ibrutinib for chronic lymphocytic...
Characterizing health related quality of life among individuals living with non-small cell lung in the United States: Findings from the Cancer Experience Registry.
11154 Background: Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC), which c...
Predicting the uptake of free cancer screening services in rural India using machine learning tools.
e22523 Background: 1,413,316 cancer cases and 916,827 cancer deaths were reported in India in 2022 (Globocan, 2022); the incidence is estimated to increas...
Impact of fine particulate matter exposure on breast cancer mortality: A county-level analysis in the United States.
e13169 Background: Fine particulate matter (PM2.5) air pollution is a known environmental risk factor for various health outcomes, including cancer. Breas...
Incidence and survival trends in early-onset colorectal cancer.
e15713 Background: Early-onset colorectal cancer (EOCRC) is colorectal cancer that occurs in people under the age of 50 and represents an emerging public...
Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs).
5056 Background: DARO is a unique AR antagonist, with preclinical studies suggesting activity in mCRPC models resistant to abiraterone or enzalutamide due...
Engineering PBAE nanoparticles for immunological reprogramming in clinically relevant humanized mouse models.
e14042 Background: Standard of care for high-grade brain tumors involves surgical resection, followed by radiotherapy, leading to long recovery times. Nan...
Immune profiling to identify predictive biomarkers and highlights the potential efficacy of IL-6R blockade in checkpoint inhibitor–related myocarditis.
12118 Background: Immune checkpoint inhibitor–associated myocarditis (ICI-My) is a rare but potentially life-threatening complication. Advancing our under...
The potential benefits of trilaciclib on blood product utilization and neutropenic fever episodes in small cell lung cancer patients: A propensity-matched cohort study.
e20134 Background: Cytotoxic chemotherapy is associated with multilineage myelosuppression, which may lead to life-threatening hematologic complications a...
Immune checkpoint blockade in locally advanced rectal cancer with deficient mismatch repair (dMMR): Retrospective multicenter experience.
e15628 Background: Total neoadjuvant therapy (TNT) with cytotoxic chemotherapy and chemoradiation followed by surgical resection is a standard treatment f...
Nimotuzumab plus chemotherapy in the posterior-line treatment for lung adenocarcinoma with third-generation epidermal growth factor receptor-tyrosine kinase inhibitors resistance.
e20636 Background: Nimotuzumab (a humanized monoclonal antibody) has shown antitumor activity in lung adenocarcinoma. We aimed to evaluate the efficacy an...
Neoadjuvant SBRT followed by evorpacept and pembrolizumab in HPV-mediated head and neck squamous cell carcinoma: Investigation of pathologic response.
e18101 Background: Recent attempts to de-escalate nonsurgical treatment for HPV mediated (HPV+) head and neck squamous cell carcinoma (HNSCC) have not bee...